EL7.AI
StocksMedium•18 November 2026•
4 min read

Convatec Raises 2026 Organic Revenue Growth Guidance to Up to 7%

Key Facts

1Convatec raised its 2026 organic revenue growth forecast, excluding InnovaMatrix, to 6.25–7.0% from 5.5–6.5%.
2Organic growth was 6.6% excluding InnovaMatrix and 3.7% including it, while reported revenue growth was 4.8% through 31 October 2026.
3The company expects InnovaMatrix revenue of about $5 million in 2026, versus a previous range of $5 million to $10 million.
4Convatec kept its adjusted operating margin forecast at at least 23%, with double-digit growth in adjusted earnings per share.

In a trading update issued on 18 November, Convatec raised its guidance for organic group revenue growth in fiscal 2026, excluding InnovaMatrix, to a range of 6.25% to 7.0%, from 5.5% to 6.5% previously. The company said the decision reflected performance in the ten months to 31 October, and that revenue growth accelerated in the second half as expected. Year-to-date organic growth was 6.6% excluding InnovaMatrix, but fell to 3.7% when it was included, while reported revenue growth was 4.8%. The gap shows that stronger growth in other activities was not fully reflected in the overall figures, as the company also lowered its estimate for InnovaMatrix revenue for the fiscal year. The chief executive said: "Revenue growth accelerated in the second half, as we expected."

The strongest performance came from Advanced Wound Care, where year-to-date growth accelerated to the mid- to high-single digits, according to the company update. Convatec attributed this to an increase in new patient numbers in the US, alongside continued strong growth elsewhere. On the back of this momentum, it raised its fiscal 2026 growth guidance for the activity to the mid- to high-single digits, compared with previous guidance for the mid-single digits. The revision represents an improvement in the annual outlook from the company's target before the update. The company did not specify in the published information how much the US and other markets each contributed to growth.

Growth in the Infusion Care business also accelerated to a double-digit rate year to date, and Convatec said its 2026 growth outlook for the activity had risen to double digits from the high-single digits. The company linked performance to accelerating growth in its diabetes business in the second half, continued strength in AbbVie's Parkinson's therapy, and higher manufacturing volumes following improved operational execution. It said better execution helped it meet rising demand, while additional production capacity is expected to come online in 2027. This places the current improvement in production in the context of a coming capacity expansion, with the activity's annual growth outlook remaining above the previous estimate. The update gave no detailed figures on the scale of demand or expected production capacity.

By contrast, Convatec lowered its 2026 revenue forecast for InnovaMatrix to about $5 million, from a previous range of $5 million to $10 million. The revision came alongside the company's higher group growth guidance excluding InnovaMatrix, while organic growth in the ten months was 3.7% including it, versus 6.6% excluding it. The group's reported revenue growth was 4.8% over the same period. These figures show the effect of how InnovaMatrix is included on the reading of group growth, without changing the company's description of revenue acceleration in the second half. The company thus set an estimate closer to the lower end of its previous revenue range for the activity.

The company kept its 2026 adjusted operating margin guidance at at least 23%, alongside its expectation of double-digit growth in adjusted earnings per share. It said the margin estimate includes a negative foreign exchange impact of about 65 basis points and pressure of about 90 basis points from InnovaMatrix. The revenue update therefore raised annual growth expectations while leaving the adjusted margin and earnings guidance in the update unchanged. The company did not provide a new adjusted earnings-per-share figure in these points, describing expected growth as double digit. The update also made no change to the minimum target for adjusted operating margin.

On investment, Convatec expects total capital expenditure in 2026 to reach the upper end of its $200 million to $230 million range, and growth capital expenditure to reach the upper end of the $135 million to $165 million range. It said its $200 million share buyback programme remains on track for completion during fiscal 2026. The elevated growth spending comes as the company anticipates new production capacity for Infusion Care coming online in 2027, according to the update. Convatec also reaffirmed its medium-term targets: organic revenue growth of 6% to 8%, double-digit growth in adjusted earnings per share, and an adjusted operating margin reaching the mid-20s from 2027. In market data cited by EL7, CTEC.L closed at 246.8 pence on 17 November; the data did not include session highs or lows.

Open on chart